STAT+: Roche continues to look to China for new drugs

AltruBio’s ulcerative colitis drug data, Merck to buy Silence Therapeutics, and more biotech news SEBASTIEN BOZON/AFP via Getty Images Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. I haven’t yet watched the new Elizabeth Holmes documentary, so I haven’t yet read this review by Theranos whistleblower Tyler Schultz (since it contains spoilers). But if you’ve seen the movie, go ahead and read the review (and don’t spoil anything for me). Roche continues to look to China for new drugs China’s Hansoh Pharmaceutical Group said yesterday it struck a massive deal with Roche to develop a portfolio of antibody-drug conjugates. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. West Coast Biotech & Life Sciences Reporter Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27.